Jubilant Ingrevia Limited — Investor Meet, 28-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Jubilant Ingrevia Limited reported strong Q2 FY25 results, showcasing significant year-on-year growth in its Specialty Chemical and Nutrition segments. Key highlights include a $300 million CDMO contract and recognition as a Global Lighthouse from the WEF. The company anticipates improved performance in H2 FY25, with a focus on customer-centric strategies and operational efficiency. Future CAPEX plans are aimed at enhancing capacity in high-margin segments, maintaining a goal of substantial revenue and EBITDA growth as part of its Pinnacle 345 vision.